Dr. Sylvia Wojczewski, CEO of BioSpring: “With our investment in Offenbach, we are setting new standards in nucleic acid drug substance manufacturing,” explained Wojczewski. “In the future, we’ll be able to produce nucleic acids for therapeutic applications on a ton scale. This allows us to support our clients’ growth by offering new high-volume capacity. The investment underscores our position as a global leading industrial manufacturer of synthetic nucleic acids.”
The new building complex will include three interconnected structures: a manufacturing and warehouse facility, an office area for quality control and production teams, and a glass atrium designed for events. An external solvent tank farm will also be built. Production will be conducted under GMP (Good Manufacturing Practice) conditions, a quality standard that ensures the highest levels of product quality, purity, and safety. In total, the complex will offer over 15,200 m² (approx. 164,000 ft²) of gross floor area and will employ around 200 people. In the long term, BioSpring aims to create additional jobs at the Innovation Campus in Offenbach. The investment amounts to several hundred million euros, with completion planned for the end of 2027.
“The city of Offenbach has supported our project from day one, from every level of staff up to the mayor himself. Even in challenging moments, everyone has been focused on finding solutions. We feel reassured in our decision to choose Offenbach,” said Wojczewski, also commending the regional government office in Darmstadt for their professional collaboration.
With nearly three decades of experience, BioSpring is a leading company and commercial provider specializing in the manufacturing and analysis of therapeutic nucleic acids, particularly oligonucleotides, from small preclinical quantities to full-scale commercial production. These short, synthetically produced RNA sequences hold the potential for groundbreaking new therapies, including treatments for cancer and Alzheimer’s disease. They also offer entirely new therapeutic possibilities for the treatment of rare genetic disorders—potentially enabling the complete cure of diseases that were previously considered incurable.
With the investments now underway in Offenbach, BioSpring will further strengthen its global leadership in the production and analysis of synthetic nucleic acids.
Comments powered by CComment